About IOS | Immune Oncology Systems (IOS)

Who We Are

Immune Oncology Systems, Inc. (IOS) and Jinan Jiazuo Pharmaceutical Technology Co., Ltd. are the core R&D platforms of Baofa Medical Group.

We adhere to a "China-US dual-core drive" strategy and are dedicated to developing and commercializing breakthrough tumor treatment options centered on our "Cancer Immune Surgery" paradigm worldwide — extending immunotherapy from late-stage systemic treatment into the perioperative period, so the tumor is immunologically primed before it is ever removed.

With an endogenous "R&D – clinical – industry" integrated ecosystem spanning our own hospital network, we ensure a full internal cycle from clinical need discovery to rapid product validation — over 80,000 patients treated across more than 26 years, including patients from 10+ countries.

25th Anniversary of First Baofa Hospital Opening

Our Hospital Network

A clinical foundation built over a quarter-century.

Our therapies are delivered through a growing network of partner and affiliated hospitals in China — including Beijing Baofa Cancer Hospital, Jinan Xicheng Hospital, and Taimei Baofa Cancer Hospital — marking the 25th anniversary of our first hospital's opening.

This clinical network is where our "R&D – clinical – industry" ecosystem lives day to day, and where community access programs — such as free treatment assistance for eligible, non-metastatic pancreatic cancer patients — are administered directly.

Cooperation agreement signing ceremony with Prof. Craig C. Mello

A Nobel Laureate Partnership

Formalizing world-class scientific oversight.

IOS has formalized a cooperation agreement appointing Professor Craig C. Mello — 2006 Nobel Prize winner in Physiology or Medicine for the discovery of RNA interference (RNAi) — as Chief Scientist of our Bioethics Medical Honors Program, guiding the scientific rigor behind our RNAi and RNA vaccine research to extend UMIPIC's efficacy and durability.

Honors & Patents

Chinese Patent of Slow Release Depot Therapy

U.S. Patent of Slow Release Depot Therapy

Australian Patent of Slow Release Depot Therapy

US patent of organ targeted therapy

Invention patent: a multifunctional therapy assisted robot

Utility model patent: a temperature controller for hyperthermia equipment

Utility model patent: a puncture instrument clamping guide device

Utility model patent: a drug mixing device for auxiliary therapy robots

Utility model patent: an ozone gas injection therapy device

Utility model patent: a needle insertion mechanism for percutaneous puncture

World-Class Leadership Team

Professor Baofa Yu

Founder

Inventor of Immunosustained-release library therapy (UMPIC) and foreign academician of the Russian Academy of Natural Sciences. Postdoctoral research at UCSD and Salk Institute. Recipient of "Outstanding Entrepreneurship Award for Overseas Chinese Professionals".

Professor Craig C. Mello

Chief Scientist

2006 Nobel Prize winner in Physiology or Medicine for "Discovery of RNA interference (RNAi)". Distinguished Professor at UMass Medical School and former co-director of the RNA Therapy Institute.

Prof. Ashok K. Saluja, Ph.D.

Scientific Advisor

Current Secretary General and former President of the American Pancreatic Association (APA). Internationally recognized authority on pancreatic disease research with over 130 SCI academic papers.